The Greenland shark’s retina stays pristine for four centuries thanks to relentless DNA repair genes—offering the first blueprint for stopping human age-related blindness.
Why This Changes Everything
Humans lose up to 90 % of rod photoreceptors by age 100. Greenland sharks keep every single one—while swimming 9 500 ft down in −1 °C water under crushing pressure. A January 2026 Nature paper reveals the animal runs a 24/7 DNA-repair protocol that pharmaceutical labs are already racing to replicate.
The Deep-Sea Paradox
Scientists long assumed the sharks were blind. Parasitic copepods latch onto their corneas, and sunlight is almost nonexistent at depth. Yet tracking data show the sharks ambush live seals and pilfer fish from nets—tasks impossible without razor-sharp vision.
What the Basel–Copenhagen Team Actually Did
Between 2020 and 2024, researchers extracted 42 eyes from sharks accidentally caught off Disko Island, Greenland. Each globe was dissected within 30 min, fixed, and subjected to genomics, transcriptomics, mass spectrometry, and micro-spectrophotometry. The oldest specimen was radiocarbon-dated at 392 years.
Three Discoveries That Stunned the Lab
- Zero cone genes active: The retina is 100 % rod cells, tuned to the faintest bioluminescent flicker.
- No DNA fragmentation: TUNEL assays—standard for spotting cell death—returned negative across every layer, even in near-four-century-old tissue.
- Repair genes on overdrive: XRCC1, OGG1, and PARP1 expression was 8–12× higher than in human fetal retinas, indicating constant base-excision repair.
Human Retinas Fall Apart—Shark Retinas Don’t
A 70-year-old human retina shows 30 % rod loss and widespread mitochondrial DNA deletions. The sharks’ persistent repair cascade keeps their photoreceptor nuclei pristine, suggesting a drugable pathway that could halt or reverse macular degeneration and retinitis pigmentosa.
From Shark to Shelf: What Happens Next
Gene-therapy startups are already synthesizing shark-derived PARP1 enhancers. The first rodent trials—injecting engineered enzymes into the sub-retinal space—launch in Q3 2026. If safety holds, human doses could enter the clinic before 2030, potentially preserving sight for millions of aging patients.
Stay locked to onlytrustedinfo.com for the fastest breakdown of the trials, the funding races, and exactly when you—or your parents—could see the benefits.
